PHARMACEUTICAL

PRIYANKA RAVALROLL NO:17070

INTRODUCTION

PHARMACY

Science dealing with collection, preparation, and standardization

of DRUGS,derives its name from the Greek

root PHARMAKON, a drug

Relating to drugs used in medical

treatment

a company that makes and sells

pharmaceuticals

Pharmacy began in Van Diemen's Land with the supply of medicines by military surgeons  and dispensers

As the number of free settlers grew, traders with ‘chemical knowledge' brought in shipments of medicines and chemicals

The first was Michael Bates who, in 1825, established a business as 'PHARMACOPOLIST, Chemist and Druggist' in Launceston

Hatton & Laws Chemists, one of the oldest pharmacy businesses still operating in Australia

Chemists were licensed by laws enacted in 1837, 1840 and 1842

Established the H.T. Gould & Co. Homeopathic Pharmacy in Hobart in 1881

 Formal separation of medicine and pharmacy came about when the Pharmacy Act was passed in 1908

Most medicines were compounded mixtures of natural ingredients until the early 1900s, when the advent of patent medicines and manufactured tablets such as ASPIRIN AND PHENACETIN

The synthesis of antibiotics and antipsychotics revolutionized drug treatment in the 1940s and 1950s

In 1978 Pharmacy moved to the University of Tasmania, where it came to be ranked as one of the best pharmacy courses in Australia.

INVOLVEMENT OF PHARMACEUTICALS IN INDIAn SECTOR

PharmaceuticalsOther

PHARMACEUTICALS

BIOTECHNOLOGY

PHARMAC-EUTICAL MARKETI

NG

TAXES OF PHARMAC

-EUTICALS

Government support &

Foreign investment

productssold to the consumers

&Consumer prefer

products

FURTHER WILL BE CONTINUED BY

MAYUR .S. AHUJAROLL no:17091

-PHARMACEUTICALS-BIOTECHNOLOGY

OVERVIEW - PHARMACEUTICALS

Fastest growing pharmaceuticals market.

12% annually in last 5 years.

Pharmaceuticals market was worth Rs. 66,400 crore in 2007-08, the domestic retail market is expected to reach around USD 13 billion by 2012.

EXPORTS

By 2012, exports are Expected to touch USD 23.5Billion(RS. 94,000 crore ).

India is the worlds fifth-largest producer of bulk drugs.

GLOBAL PHARMACEUTICAL COMPANIES ATTRACTED TO INDIA

Since January 2005, about 15patented products have beenlaunched in the country.

OVERVIEW - BIOTECHNOLOGY

India is among top 12 biotech markets globally.

India ranks third in Asia-Pacificregion, after Japan n Korea.

THE PHARMACEUTICAL HUB

FURTHER WILL BE CONTINUED BY

Akshay raneROLL no:17066

Pharmaceuticals productssold to the consumers

&Consumer prefer products.

Selling of products to the consumer is depend upon some Demographic changes :-

Consumer’s healthcareSegments:-

1. Personal care2. Scientifically based

1. Personal care:- Companies Persuade Consumers that their products are testy and healthy. Promise to deliver health benefits in pharmaceuticals products. Companies provides specific health needs or increase some dimension of performance. Pharmaceuticals companies expands their business beyond the over the counter market (expand business on large scale).

2. Scientific based care:- Companies encouraging peoples that their products are scientifically based. Companies focusing on growth and profitability. E.g.. Nestle company starts consumer health business. Product should be organize or manage by experts persons.

Consumer prefer products depends upon:-

Increased focus on Public health. Increased consumers spending. New spending due to increased in population.

FURTHER WILL BE CONTINUED BYBrijesh yadavROLL no:17088

PHARMACEUTICAL MARKETINGPharmaceutical marketing, sometimes called medico-marketing or pharma marketing in some countries, is the business of advertising or otherwise promoting the sale of pharmaceuticals or drugs. There is some evidence that marketing practices can negatively affect both patients and the health care profession. Many countries have measures in place to limit advertising by pharmaceutical companies.

. Marketing of legitimate medications, such as pain relievers or allergy medicine, has also long been practiced, although, until recently, mass marketing of prescription medications has been rare. It was long believed that since doctors made the selection of drugs, mass marketing was a waste of resources; specific ads targeting the medical profession were thought to be cheaper and just as effective. An important part of these efforts was marketing to medical students.

In the United States, marketing and distribution of pharmaceuticals is regulated by the Federal Food, Drug, and Cosmetic Act and the Prescription Drug Marketing Act, respectively. Food and Drug Administration (FDA) regulations require all prescription drug promotion to be truthful and not misleading, based on "substantial evidence or substantial clinical experience",

SUPPLY CHAIN MANUFACTURER

CNF

DISTRIBUTING AGENTS

MEDICAL SHOPS CONSUMER

FREE SAMPLESFree samples have been shown to affect physician prescribing behaviour.It is argued that a benefit to free samples is the “try it before you buy it” approach. Free Samples give immediate access to the medication and the patient can begin treatment right away. Also, it saves time from going to a pharmacy to get it filled before treatment begins.free samples allows you to find which dose and brand of medication works best before having to spend money on a filled prescription at a pharmacy.

TOP COMPANIESRANK COMPANY

1 ABBOT INDIA

2 RANBAXY

3 DR.REDDY LABROTERY

4 AUROBINDO

5 CIPLA

TOTAL EXPENDITURE

THE PHARMACEUTICLE INDUSTRY IN INDIA STANDS THIRD IN THE WORLD IN CASE OF SALES. ACCORDING TO DEPARTMENT OF PHARMACEUTICLE ,MINISTERY OF CHEMICLE & FERTILIZER THE TOTL TURNOVER OF INDIAS PHARMACEUTICLE INDUSTRY IN 2008-09 WAS 21.04 BILLION.WHILE THE DOMESTIC MARKET WAS 12.26 MILLION.THE EXPENES OF SAME NOW AT 2012 IS 19.22 MILLION.

2008 in Canada $1.7 billion a year was spent marketing drugs to physicians and in the United States $21 billion were spent in 2008. In 2011 money spent on pharmaceutical marketing in the US was estimated at $29.9 billion with one estimate as high as $57 MILLION.

REGULATION & FRAUD

MISLABELLINGHIGH PRICESLOW LIFE SPANSIDE EFFECTSLIMITED TEMPERATUREDRUGS SCAMFALSE PROMOTION.BOUNDLESS EXPENSIVE.

FRAUDSCOMPANY SETTLMENT FRAUDS

GLAXOSMITH 3 BILLION FALSE PROMOTON

ELI 1.4 BILLION FALSE PROMOTON

TAP 875 MILLION MEDICARE FRAUD

SERONO 704 MILLION POOR MANF.

FURTHER WILL BE CONTINUED BY

Kamelshwaran.nROLL no:17052

Governments Support and Foreign Investments

in Pharmaceutical Industries in India

Comparison with the U.S.The Indian biotech sector parallels that of the U.S. in many ways. Both are filled with small start-ups while the majority of the market is controlled by a few powerful companies. Both are dependent upon government grants and venture capitalists for funding because neither will be commercially viable for years. Pharmaceutical companies in both countries have recognized the potential effect that biotechnology could have on their pipelines and have responded by either investing in existing start-ups or venturing into the field themselves.[36] In both India and the U.S., as well as in much of the globe, biotech is seen as a hot field with a lot of growth potential.

Relationship with ITMany analysts have observed that the hype around the biotech sector mirrors that of the IT sector. Biotech colleges have been popping up around the country eager to service the pools of students that want to take advantage of a growing industry. The International Finance Commission, the private investment arm of the World Bank, called India the “centerpiece of IFC’s global biotech strategy.” Of the $110 million invested in 14 biotech projects investment globally, the IFC has given $43 million to 4 projects in India. According to Dr. Manju Sharma, former director of the Department of Biotechnology, the biotech industry could become the “single largest sector for employment of skilled human resource in the years to come.”British Prime Minister Tony Blair was similarly impressed, citing the success of India’s biotech industry as the reason for his own country’s own biotech opportunities. Malaysia is also looking to India as an example for growing its own biotech industry.

Government supportThe Indian government has been very supportive. It established the Department of Biotechnology in 1986 under the Ministry of Science and Technology. Since then, there have been a number of dispensations offered by both the central government and various states to encourage the growth of the industry. India’s science minister launched a program that provides tax incentives and grants for biotech start-ups and firms seeking to expand and establishes the Biotechnology Parks Society of India to support ten biotech parks by 2010. Previously limited to rodents, animal testing was expanded to include large animals as part of the minister’s initiative. States have started to vie with one another for biotech business, and they are offering such goodies as exemption from VAT and other fees, financial assistance with patents and subsidies on everything ranging from investment to land to utilities.

Foreign investmentThe government has also taken steps to encourage foreign investment in its biotech sector. An initiative passed earlier this year allowed 100% foreign direct investment without compulsory licensing from the government. In April, a delegation headed by the Kapil Sibal, the minister of science and technology and ocean development, visited five cities in the U.S. to encourage investment in India, with special emphasis on biotech. Just two months later, Sibal returned to the U.S. to unveil India’s biotech growth strategy at the BIO2005 conference in Philadelphia. 100%of fdi is allowed in India.

ChallengesThe biotech sector faces some major challenges in its quest for growth. Chief among them is a lack of funding, particularly for firms that are just starting out. The most likely sources of funds are government grants and venture capital, which is a relatively young industry in India. Government grants are difficult to secure, and due to the expensive and uncertain nature of biotech research, venture capitalists are reluctant to invest in firms that have not yet developed a commercially viable product. As previously mentioned, India hopes to solve its funding problem by attracting overseas investors and partners. Before these potential saviors will invest significant sums in the industry, however, there needs to be better scientific and financial accountability. India is slowly working towards these goals, but it will be a while before they are up to the standards of Western investors.

FURTHER WILL BE CONTINUED BYAbhiyog patilROLL no:17056

TAXES OF PHARAMACEUTICALS

• GOODS AND SERVICE TAX(GST):-

INTRODUCTION

DUAL GST IN INDIA

IMPACT ON PHARMACEUTICAL INDUSTRY:-1. Procurement2. Manufacture3. Sales and distribution4. Pricing5. Services6. IT changes

• DIRECT TAX:- Tax structureIncentives to pharmaceutical sectors

• INDIRECT TAXES:-Custom dutyCentral excise dutyValue added Tax and central sales tax

Table Comparing PricesDRUGS MFG BY PRICES

INCREASE IN TAX VALUE

(approx)

RISPERIDONE(Risperdal)

Johnson & Johnson 366 491 34.15 %

RISEDRONATE(Risofos)

Cipla166 221 33.13%

CLOPIDOGREL(Noklot)

Zydus111 167 50.45%

PREGABALIN(Pregabit)

Intas Pharma 98 154 57.14%

GRAPHICAL IMPLEMENTATION

Risperidone Risedronate Clopidogrel Pregabalin0

50

100

150

200

250

300

350

400

450

366

166

111 98

491

221

167 154

20102012

Pri

ces

DRUGS

34.15 %

33.13 %

50.45 %

57.14 %

CONCLUSION

THANK YOU